Exosome-mediated aptamer S58 reduces fibrosis in a rat glaucoma filtration surgery model
Author:
Corresponding Author:

Lin Xie. Department of Ophthalmology, The Third Affiliated Hospital of Chongqing Medical University, 1 Shuanghu Road, Chongqing 401120, China. xielin@hospital.cqmu.edu.cn

Affiliation:

Clc Number:

Fund Project:

Supported by the National Natural Science Foundation of China (No.81700836; No.81470629; No.81670860); Chongqing Natural Research Foundation (No.cstc 2018jcyjAX0034).

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    AIM: To confirm whether exosome-mediated delivery of aptamer S58 (Exo-S58) has a better antifibrotic effect than naked S58 in human conjunctival fibroblasts (HConFs) and a rat glaucoma filtration surgery (GFS) model. METHODS: To enhance the effective reaction time of aptamer S58 in vivo, we loaded aptamer S58 into exosomes derived from HEK293T cells by PEI transfection to determine the effect of Exo-S58 in HConFs and a rat GFS model. RESULTS: Exo-S58 can significantly reduce cell proliferation, migration and fibrosis in TGF-β2-induced HConFs. In an in vivo experiment, Exo-S58 treatment prolonged filtering bleb retention and reduced fibrosis compared with naked S58 treatment in GFS rats. CONCLUSION: The exosomes are safe and valid carriers to deliver aptamers. Furthermore, Exo-S58 exhibited superior antifibrotic effect than naked S58 both in HConFs cells and rat GFS models.

    Reference
    Related
    Cited by
Get Citation

Qian-Yi Lin, Xiang-Ji Li, Yu Leng, et al. Exosome-mediated aptamer S58 reduces fibrosis in a rat glaucoma filtration surgery model. Int J Ophthalmol, 2022,15(5):690-700

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
Publication History
  • Received:November 19,2021
  • Revised:February 21,2022
  • Adopted:
  • Online: April 27,2022
  • Published: